Skip to main content

Our objective

Research undertaken within our Group is focused on determining the mechanisms underlying clot formation in healthy individuals; applying this knowledge to better understand the mechanisms leading to platelet hyperactivity and pathological blood clot formation; and ultimately development of safer and more effective therapies to treat cardiovascular diseases, including heart attack, stroke, diabetes and the metabolic syndrome.

Our impact

Atherothrombosis is arguably Australia’s greatest healthcare problem, affecting over 50% of the adult population. Despite intense investigation over the last 40 years into the discovery and development of more effective antithrombotic drugs, the impact of these therapies on mortality rates has remained disappointingly low. This situation is likely to worsen in the future due to the rapidly growing incidence of obesity, diabetes and the metabolic syndrome – diseases that are typically more resistant to the benefits of “classical” antithrombotic therapy. The comprehensive research approach adopted by our Group is designed to identify and target thrombosis risk in such diseases.

The team

Dr Sabine Kossman

German Research Foundation Postdoctoral Fellow

Dr Marc Ellis

PhD Student

Dr Qian (Peter) Su

Visiting Postdoctoral Fellow (UTS)

Benjamin Hofma

Research Assistant

Marissa Baptista

Research Assistant

Rhyll Smythe

Research Assistant

Ethan Italiano

Undergraduate Intern (USyd)

Savindi Ramasundara

Biomedical Engineering Honours Student

Myf Richardson

Undergraduate Intern (USyd)